Quantification Of Serum HBXAP DNA In Lung Cancer Patients By Quantitative Fluorescent Polymerase Chain Reaction

ObjectiveTo construct plasmid pMD18-T-HBXAP as standard, the FQ-PCR wasdeveloped to quantify the serum hepatitis B virus x associated protein(HBXAP) DNA of lung cancer patients. The clinical significance of serumHBXAP DNA was analyzed.Methods1. To Extract serum DNA and construct the plasmidpMD18-T-HBXAP as standard. The FQ-PCR was established to quantifythe serum HBXAP DNA，and evaluated the imprecision, specificity andlinear range.2. Collected serum and clinical characters of65lung cancer patientsand20healthy persons as control. Serum DNA was extracted andquantified by the FQ-PCR. The serum HBXAP DNA levels in lung cancerpatients with TNM stage Ⅲ-Ⅳ were higher than those with stageⅠ-Ⅱ.The levels of serum HBXAP DNA in lung cancer patients with lymph nodemetastases were higher than those without. Combining HBXAP DNA and existing tumor markers for lung cancer could increase the sensitivitynotably.Results1. Constructed the plasmid of pMD18-T-HBXAP, and developedFQ-PCR method to quantify lung cancer patients serum HBXAP DNAsuccessfully.2. Relationship between serum HBXAP DNA of lung cancer patientsand clinical characters:(1) Serum HBXAP DNA levels M (P25, P75) in lungcancer patients and healthy controls were2171.0(633.0,5366.7) and720.7(345.2,1240.6), respectively.(2) The serum HBXAP DNA levels in lungcancer patients with TNM stage Ⅲ-Ⅳ were higher than those withstageⅠ-Ⅱ, and the serum HBXAP DNA levels in lung cancer patients withlymph node metastases were higher than those without.(3) Serum HBXAPDNA levels for lung cancer showed a sensitivity of61.9%and specificity of93.7%at a cut-off of1557.6copies/μl according to the maximum Youdenindex.(4) The sensitivity Of serum HBXAP DNA was higher than theexisting tumor markers for lung cancer, such as SCC, CYFRA21-1, andNSE. When serum HBXAP DNA was combined with each of these markers,the sensitivity increased notably.ConclusionTo construct plasmid pMD18-T-HBXAP as standard and developFQ-PCR method successfully to quantify serum HBXAP DNA. The levels of serum HBXAP DNA in lung cancer patients were higher than that ofhealthy controls, and obviously related to the TNM stage and lymph nodemetastasis. Quantification of serum HBXAP DNA by FQ-PCR may be auseful biomarker for lung cancer in a clinical setting.